These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 3160131)

  • 1. Platelet-mediated vascular permeability in the rat: a predominant role for 5-hydroxytryptamine.
    De Clerck F; Van Gorp L; Beetens J; Reneman RS
    Thromb Res; 1985 May; 38(4):321-39. PubMed ID: 3160131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platelet-mediated vascular contractions: inhibition of the serotonergic component by ketanserin.
    De Clerck F; Van Nueten JM
    Thromb Res; 1982 Sep; 27(6):713-27. PubMed ID: 6817452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platelet-vessel wall interactions: implication of 5-hydroxytryptamine. A review.
    De Clerck F; van Nueten JM; Reneman RS
    Agents Actions; 1984 Dec; 15(5-6):612-26. PubMed ID: 6397984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 5-Hydroxytryptamine and the metabolism of arachidonic acid by the lipoxygenase and cyclooxygenase of washed human platelets.
    Dragan YP; Ellis EF
    Biochem Pharmacol; 1990 Jul; 40(2):309-14. PubMed ID: 2142882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prolongation of rat tail bleeding time by ketanserin: mechanisms of action.
    Buczko W; Gambino MC; De Gaetano G
    Eur J Pharmacol; 1984 Aug; 103(3-4):261-8. PubMed ID: 6237923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of PAF on rat lung vascular permeability: role of platelets and polymorphonuclear leucocytes.
    Sirois MG; de Lima WT; de Brum Fernandes AJ; Johnson RJ; Plante GE; Sirois P
    Br J Pharmacol; 1994 Apr; 111(4):1111-6. PubMed ID: 8032597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Arachidonate metabolism, 5-hydroxytryptamine release and aggregation in human platelets activated by palmitaldehyde acetal phosphatidic acid.
    Brammer JP; Maguire MH
    Br J Pharmacol; 1984 May; 82(1):61-72. PubMed ID: 6428500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The involvement of 5-HT2-receptor sites in the activation of cat platelets.
    De Clerck F; Xhonneux B; Leysen J; Janssen PA
    Thromb Res; 1984 Feb; 33(3):305-21. PubMed ID: 6710435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Platelet-vessel wall interactions in hemostasis: implication of 5-hydroxytryptamine.
    De Clerck F; Somers Y; Van Gorp L
    Agents Actions; 1984 Dec; 15(5-6):627-35. PubMed ID: 6543415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Platelet-mediated vascular contractions. Inhibition by flunarizine, a calcium-entry blocker.
    De Clerck F; Van Nueten JM
    Biochem Pharmacol; 1983 Mar; 32(5):765-71. PubMed ID: 6404280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An extract of rat submandibular glands activates platelets and enhances cutaneous vascular permeability in rats and guinea pigs.
    Cox CP; Lerner MR; Wood KL
    Life Sci; 1986 Nov; 39(20):1917-25. PubMed ID: 3773648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 5-hydroxytryptamine and precapillary vessels.
    Van Nueten JM
    Fed Proc; 1983 Feb; 42(2):223-7. PubMed ID: 6295823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological profile of a new potent 5-hydroxytryptamine (5-HT2) alpha 1-receptor antagonist.
    Schröder G; Beckmann R; Gerbling KP; Loge O; Maass B; Müller B; Seidelmann D; Schneider HH; Schulz BG; Stürzebecher CS
    Arzneimittelforschung; 1988 Jun; 38(6):765-70. PubMed ID: 2902861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological profiles of R-96544, the active form of a novel 5-HT2A receptor antagonist R-102444.
    Ogawa T; Sugidachi A; Tanaka N; Fujimoto K; Asai F
    Eur J Pharmacol; 2002 Dec; 457(2-3):107-14. PubMed ID: 12464356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathways responsible for platelet hypersensitivity in rats with diabetes. I. Streptozocin-induced diabetes.
    Winocour PD; Kinlough-Rathbone RL; Mustard JF
    J Lab Clin Med; 1986 Feb; 107(2):148-53. PubMed ID: 3080538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of adenosine in platelet-mediated reduction in pulmonary vascular permeability.
    Paty PS; Sherman PF; Shepard JM; Malik AB; Kaplan JE
    Am J Physiol; 1992 Mar; 262(3 Pt 2):H771-7. PubMed ID: 1558187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blood platelets and the inflammatory process.
    Silver MJ; Smith JB; Ingerman CM
    Agents Actions; 1974 Oct; 4(4):233-40. PubMed ID: 4447066
    [No Abstract]   [Full Text] [Related]  

  • 18. Vascular reactivity in diabetes mellitus: possible role of insulin on the endothelial cell.
    Fortes ZB; Garcia Leme J; Scivoletto R
    Br J Pharmacol; 1984 Nov; 83(3):635-43. PubMed ID: 6439270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of LY53857, a selective 5HT2 receptor antagonist, on 5HT-induced increases in cutaneous vascular permeability in rats.
    Cohen ML; Schenck K
    Life Sci; 1989; 44(14):957-61. PubMed ID: 2927252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AHR-16303B, a novel antagonist of 5-HT2 receptors and voltage-sensitive calcium channels.
    Barrett RJ; Appell KC; Kilpatrick BF; Proakis AG; Nolan JC; Walsh DA
    J Cardiovasc Pharmacol; 1991 Jan; 17(1):41-53. PubMed ID: 1708055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.